EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma

Daniela Lorizio, Manuela Silginer, Julia Friesen, Alan L Epstein, Michael Weller, Patrick Roth

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04098-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Daniela Lorizio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerlan…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Glucocorticoid-Induced TNFR-Related Protein, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eurostars, Universität Zürich, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunosuppressive tumor microenvironment of glioblastoma limits the effectiveness of most immunotherapies. Transforming growth factor (TGF)-β signaling drives tumor progression and prevents effective T cell activity. Notably, both regulatory T cells (Tregs) and effector T cells within glioblastoma and other tumors express high levels of the immune checkpoint receptor, glucocorticoid-induced tumor necrosis factor receptor (GITR), which modulates T cell activation and function. Combining GITR agonism with TGF-β inhibition may therefore offer a compelling approach to restore anti-tumor immunity. We evaluated the combined effects of TGF-β inhibition and GITR modulation using two different GITR agonists in syngeneic mouse glioma models. GITR modulation enhanced T cell activation, as shown by increased cytokine secretion and effector T cell proliferation in vitro. Combining GITR modulation with TGF-β inhibition amplified these effects, resulting in significantly stronger immune cell-mediated tumor cell killing compared to single-agent treatments. Combination therapy improved survival of glioma-bearing mice, with a higher fraction of long-term survivors compared to monotherapy. Surviving mice resisted tumor re-challenge, indicating durable adaptive immunity. In summary, dual targeting of TGF-β and GITR pathways synergistically enhances anti-tumor immunity in glioblastoma. This novel combination strategy demonstrates clinical potential by addressing the limitations of existing immunotherapies and offering a promising approach for durable and effective glioblastoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor betaGlucocorticoid-Induced TNFR-Related ProteinGliomaBrain NeoplasmsAnimalsMiceHumansSignal TransductionMice, Inbred C57BLTumor MicroenvironmentCell Line, TumorImmunotherapyFemaleT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

GITRLGlioblastomaImmunosuppressionImmunotherapyMicroenvironment

Substanzen

Transforming Growth Factor betaGlucocorticoid-Induced TNFR-Related ProteinTnfrsf18 protein, mouse

Autor:innen und Institutionen

  • Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.
  • Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. patrick.roth@usz.ch.

Förderung

  • Eurostars
  • Universität Zürich
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • University of Zurich

Zitieren

APA

Lorizio, D., Silginer, M., Friesen, J., Epstein, A. L., Weller, M., & Roth, P. (2025). Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04098-w

Vancouver

Lorizio D, Silginer M, Friesen J, Epstein AL, Weller M, Roth P. Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04098-w

BibTeX
@article{Lorizio2025,
  author = {Lorizio, Daniela and Silginer, Manuela and Friesen, Julia and Epstein, Alan L and Weller, Michael and Roth, Patrick},
  title = {Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04098-w}
}
Kostenlos starten →